BridgeBio Pharma (BBIO) Enterprise Value (2019 - 2026)

BridgeBio Pharma has reported Enterprise Value for 9 years, with the latest figure at -$929.7 million in Q1 2026.

• Quarterly Enterprise Value fell 75.21% year-over-year to -$929.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$929.7 million (down 75.21% YoY) and the FY2025 annual result came in at -$576.9 million, down 65.0% from the prior year.
• Enterprise Value retreated to -$929.7 million in Q1 2026 per BBIO's latest filing, from -$576.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$255.4 million in Q3 2024 and troughed at -$929.7 million in Q1 2026.
• A 5-year average of -$477.0 million and a median of -$463.2 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value jumped 55.44% in 2022, then slumped 75.21% in 2026.
• Over 5 years, Enterprise Value stood at -$403.3 million in 2022, then gained by 5.45% to -$381.3 million in 2023, then rose by 8.32% to -$349.6 million in 2024, then slumped by 65.0% to -$576.9 million in 2025, then sank by 61.17% to -$929.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$929.7 million, -$576.9 million, and -$276.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.